This post-authorization observational safety study determines the characteristics of patients prescribed naloxegol at time of first prescription and treatment patterns of naloxegol in follow-up in the United Kingdom (UK), Norway, Sweden, and Germany.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
discontinuation
Timeframe: can occur anytime through study completion, given no fixed follow-up timepoints, which can range from 1 day to 3 years
Switching
Timeframe: can occur anytime through study completion, given no fixed follow-up timepoints, which can range from 1 day to 3 years
Augmentation
Timeframe: can occur anytime through study completion, given no fixed follow-up timepoints, which can range from 1 day to 3 years
Restart
Timeframe: can occur anytime through study completion, given no fixed follow-up timepoints, which can range from 1 day to 3 years
Continuous Use
Timeframe: can occur anytime through study completion, given no fixed follow-up timepoints, which can range from 1 day to 3 years
Dose Change
Timeframe: can occur anytime through study completion, given no fixed follow-up timepoints, which can range from 1 day to 3 years